Does the media refer more to EXEL or EWTX?

In the previous week, Exelixis had 3 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 9 mentions for Exelixis and 6 mentions for Edgewise Therapeutics. Exelixis' average media sentiment score of 0.34 beat Edgewise Therapeutics' score of 0.29 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to ASND or EWTX?

In the previous week, Edgewise Therapeutics had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 6 mentions for Edgewise Therapeutics and 2 mentions for Ascendis Pharma A/S. Edgewise Therapeutics' average media sentiment score of 0.29 beat Ascendis Pharma A/S's score of 0.25 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to BBIO or EWTX?

In the previous week, BridgeBio Pharma had 6 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 12 mentions for BridgeBio Pharma and 6 mentions for Edgewise Therapeutics. BridgeBio Pharma's average media sentiment score of 0.49 beat Edgewise Therapeutics' score of 0.29 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to HALO or EWTX?

In the previous week, Halozyme Therapeutics had 16 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 22 mentions for Halozyme Therapeutics and 6 mentions for Edgewise Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.61 beat Edgewise Therapeutics' score of 0.29 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, SMMT or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A

Is SMMT or EWTX more profitable?

Edgewise Therapeutics' return on equity of -39.01% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Edgewise Therapeutics N/A -39.01% -36.96%

Does the media favor SMMT or EWTX?

In the previous week, Summit Therapeutics had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 7 mentions for Summit Therapeutics and 6 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.29 beat Summit Therapeutics' score of 0.26 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Edgewise Therapeutics (EWTX) Competitors

$39.06 -0.17 (-0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$39.60 +0.54 (+1.39%)

As of 07:30 PM Eastern

Compare

EWTX vs. EXEL, ASND, BBIO, HALO, and SMMT

Should you buy Edgewise Therapeutics stock or one of its competitors? Edgewise Therapeutics's main competitors and comparable companies include Exelixis (EXEL), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO), and Summit Therapeutics (SMMT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Edgewise Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Exelixis has a net margin of 35.33% compared to Edgewise Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Exelixis has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.30	$782.57M	$3.18	18.56
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

85.3% of Exelixis shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Exelixis currently has a consensus target price of $50.36, indicating a potential downside of 14.68%. Edgewise Therapeutics has a consensus target price of $51.33, indicating a potential upside of 30.85%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Edgewise Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Exelixis has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

In the previous week, Exelixis had 3 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 9 mentions for Exelixis and 6 mentions for Edgewise Therapeutics. Exelixis' average media sentiment score of 0.34 beat Edgewise Therapeutics' score of 0.29 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Exelixis beats Edgewise Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Ascendis Pharma A/S has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Edgewise Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.05	-$258M	$12.89	17.28
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

In the previous week, Edgewise Therapeutics had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 6 mentions for Edgewise Therapeutics and 2 mentions for Ascendis Pharma A/S. Edgewise Therapeutics' average media sentiment score of 0.29 beat Ascendis Pharma A/S's score of 0.25 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ascendis Pharma A/S has a net margin of 70.99% compared to Edgewise Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Ascendis Pharma A/S currently has a consensus target price of $310.75, suggesting a potential upside of 39.54%. Edgewise Therapeutics has a consensus target price of $51.33, suggesting a potential upside of 30.85%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Ascendis Pharma A/S beats Edgewise Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Edgewise Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Edgewise Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.32	-$724.93M	-$3.57	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Edgewise Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

BridgeBio Pharma currently has a consensus target price of $105.42, suggesting a potential upside of 62.09%. Edgewise Therapeutics has a consensus target price of $51.33, suggesting a potential upside of 30.85%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe BridgeBio Pharma is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, BridgeBio Pharma had 6 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 12 mentions for BridgeBio Pharma and 6 mentions for Edgewise Therapeutics. BridgeBio Pharma's average media sentiment score of 0.49 beat Edgewise Therapeutics' score of 0.29 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

BridgeBio Pharma beats Edgewise Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

In the previous week, Halozyme Therapeutics had 16 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 22 mentions for Halozyme Therapeutics and 6 mentions for Edgewise Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.61 beat Edgewise Therapeutics' score of 0.29 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Halozyme Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Halozyme Therapeutics has a net margin of 24.86% compared to Edgewise Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Halozyme Therapeutics currently has a consensus target price of $94.00, indicating a potential downside of 14.42%. Edgewise Therapeutics has a consensus target price of $51.33, indicating a potential upside of 30.85%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Halozyme Therapeutics has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.93	$316.89M	$3.35	32.79
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

Summary

Halozyme Therapeutics beats Edgewise Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

Edgewise Therapeutics' return on equity of -39.01% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Summit Therapeutics has a beta of -1.51, suggesting that its stock price is 251% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

In the previous week, Summit Therapeutics had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 7 mentions for Summit Therapeutics and 6 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.29 beat Summit Therapeutics' score of 0.26 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summit Therapeutics currently has a consensus price target of $28.61, indicating a potential upside of 66.61%. Edgewise Therapeutics has a consensus price target of $51.33, indicating a potential upside of 30.85%. Given Summit Therapeutics' higher probable upside, equities analysts plainly believe Summit Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Summit Therapeutics beats Edgewise Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Edgewise Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EWTX vs. The Competition

Export

Metric	Edgewise Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.26B	$3.90B	$7.20B	$13.28B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	N/A	13.55	274.76	26.18
Price / Sales	N/A	1,283.29	632.15	98.25
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	7.92	17.17	11.21	6.34
Net Income	-$167.79M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-5.65%	-1.20%	-0.84%	-1.39%
1 Month Performance	-9.98%	-9.68%	-5.42%	-4.31%
1 Year Performance	143.36%	10.09%	4.38%	-0.35%

Edgewise Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EWTX Edgewise Therapeutics	2.824 of 5 stars	$39.06 -0.4%	$51.33 +31.4%	+155.6%	$4.26B	N/A	N/A	127
EXEL Exelixis	2.4643 of 5 stars	$58.65 +0.5%	$50.29 -14.3%	+52.7%	$14.46B	$2.32B	18.44	1,077	Trending News Analyst Forecast Analyst Revision
ASND Ascendis Pharma A/S	4.7897 of 5 stars	$228.07 -0.9%	$310.75 +36.3%	+6.0%	$14.35B	$814.57M	17.69	1,189
BBIO BridgeBio Pharma	3.9617 of 5 stars	$65.97 -1.0%	$102.61 +55.5%	+17.6%	$13.02B	$502.08M	N/A	839	Analyst Forecast
HALO Halozyme Therapeutics	3.5021 of 5 stars	$111.56 -1.2%	$91.20 -18.3%	+68.5%	$12.81B	$1.40B	33.30	423	Trending News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EWTX) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. EXEL, ASND, BBIO, HALO, and SMMT

How does Edgewise Therapeutics compare to Exelixis?

Summary

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Summary

How does Edgewise Therapeutics compare to Halozyme Therapeutics?

Summary

How does Edgewise Therapeutics compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. EXEL, ASND, BBIO, HALO, and SMMT

How does Edgewise Therapeutics compare to Exelixis?

Is EXEL or EWTX more profitable?

Which has preferable valuation & earnings, EXEL or EWTX?

Do insiders and institutionals believe in EXEL or EWTX?

Do analysts rate EXEL or EWTX?

Which has more volatility and risk, EXEL or EWTX?

Does the media refer more to EXEL or EWTX?

Summary

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Which has more volatility and risk, ASND or EWTX?

Which has better earnings & valuation, ASND or EWTX?

Does the media refer more to ASND or EWTX?

Is ASND or EWTX more profitable?

Do analysts rate ASND or EWTX?

Summary

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Which has more risk and volatility, BBIO or EWTX?

Which has preferable earnings & valuation, BBIO or EWTX?

Do insiders & institutionals have more ownership in BBIO or EWTX?

Is BBIO or EWTX more profitable?

Do analysts prefer BBIO or EWTX?

Does the media refer more to BBIO or EWTX?

Summary

How does Edgewise Therapeutics compare to Halozyme Therapeutics?

Does the media refer more to HALO or EWTX?

Which has more risk & volatility, HALO or EWTX?

Is HALO or EWTX more profitable?

Do analysts prefer HALO or EWTX?

Do insiders and institutionals believe in HALO or EWTX?

Which has stronger earnings & valuation, HALO or EWTX?

Summary

How does Edgewise Therapeutics compare to Summit Therapeutics?

Do institutionals and insiders have more ownership in SMMT or EWTX?

Which has stronger valuation and earnings, SMMT or EWTX?

Is SMMT or EWTX more profitable?

Which has more volatility and risk, SMMT or EWTX?

Does the media favor SMMT or EWTX?

Do analysts prefer SMMT or EWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools